Relatively High Projected Earnings Growth Detected in Shares of Ligand Pharmaceuticals in the Biotechnology Industry (LGND, GILD, RGEN, CELG, EBS)
Below are the three companies in the Biotechnology industry with the highest projected earnings growth. The growth of earnings per share (current fiscal year estimated vs. last year actual) is important to gauge future profitability and relative value. Higher EPS growth generally justifies higher earnings multiples.
Ligand Pharmaceuticals ranks highest with a projected earnings growth of 120.4%. Following is Gilead Sciences with a projected earnings growth of 50.2%. Repligen ranks third highest with a projected earnings growth of 48.0%.
Celgene follows with a projected earnings growth of 29.7%, and Emergent Biosolutions rounds out the top five with a projected earnings growth of 27.7%.
SmarTrend recommended that its subscribers protect gains by selling shares of Emergent Biosolutions on June 16th, 2016 by issuing a Downtrend alert when the shares were trading at $40.80. Since that call, shares of Emergent Biosolutions have fallen 29.6%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.
Keywords: highest projected earnings growth ligand pharmaceuticals Gilead Sciences repligen Celgene emergent biosolutions